TORONTO, April 11 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a
wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today
that Ranbaxy has received approval to manufacture and market RAN(TM)-Cefprozil
Tablets, 250mg and 500mg, and RAN(TM)-Cefprozil Powder for Oral Suspension,
250mg/5mL from Health Canada. The total market size for Cefzil(TM)(*) in Canada
was CAD 28.2 million dollars (IMS-MAT: Dec 2006).
